With the normalization of volume procurement, the retail market space continues to grow.

"Pharmaceutical Network Market Analysis" In recent years, after the harvest, the function of hospitals as a channel for the sale of prescription drugs is becoming more and more weakened, but at the same time, China's retail market itself is beginning to change, drug separation, prescription outflow and other policies are long-term good for the expansion and growth of the retail market.
, China's three major terminal drug sales reached 1795.5 billion yuan in 2019, up 4.8% year-on-year.
, the share of public hospital terminals remains large, at 66.6% in 2019, but down from 67.4% in 2018, while the share of retail pharmacy terminals in 2019 is 23.4%, which has been growing for many years.
In addition, with the promotion of prescription outflow and other related policies, prescription outflow market continues to expand, the industry is expected to 2020 prescription outflow will bring more than 150 billion yuan in retail sales, pharmaceutical retailing in the future drug sales will also occupy an important position.
And with the expansion of the scale of the retail market, as well as the change of the logic of the domestic pharmaceutical industry, more and more pharmaceutical companies no longer only stare at the hospital market, began to target the broad out-of-hospital market, retail terminals are increasingly becoming a new focus of the layout of domestic and foreign pharmaceutical enterprises.
such as April 11, 2019, Hengrui Pharmaceutical Retail Strategy Customer Invitation Conference was held.
a number of well-known domestic chain pharmacies participated in this meeting.
, general manager of Hengrui Integrated Products Division, said that Hengrui Pharmaceuticals will use chronic disease drugs as a breakthrough in the end-use retail market in the future, hoping for strong growth in this area.
same year, The Company's controlling subsidiary, State University Pharmacy, acquired a 75% stake in Pudong Pharmaceuticals by a non-public agreement, paying a total price of not more than 163 million yuan.
In addition, The University Pharmacy intends to acquire 100% of Shanghai Dingqun's equity in cash and indirectly acquire 85% of Shanghai Dingqun's stake in State-controlled Tian, with a total payment of no more than 934 million yuan.
data show that the state-controlled Tian and is currently Jilin Province, a wholesale and retail business of a large-scale pharmaceutical circulation enterprises.
, as well as China Resources Pharmaceuticals, has 150 DTP pharmacies in 76 cities by the first half of 2019.
in the release of the 2019 mid-year report, it pointed out that during the reporting period, the company actively participated in the development of medical reform policies, prescription outflow to undertake, new special drugs (DTP) varieties of channel development and introduction, to enhance the professionalism of new special pharmacies, access to slow diagnosis and other qualifications.
has completed 35 DTP pharmacies and established a complete DTP pharmacy management system and a DTP management team.
, with the start of a new round of reshuffles in the industry, many well-known pharmaceutical companies have begun to lay out the retail market.
But it is worth noting that although the major pharmaceutical companies are currently actively layout the retail market, eager to get a piece of the prescription outflow market, but it is also facing a very big test, such as how to change business philosophy, improve the professional service capabilities of employees, to undertake the hospital prescription outflow of hardware and software preparation and other issues need to learn to deal with.
.